Wegovy maker Novo Nordisk sales rise 18% in second quarter

Novo Nordisk, the Wegovy maker, announced cost reductions and a sharpened commercial focus following a $95 billion stock loss triggered by a major profit warning and increased competition in the weight-loss drug market. The company, which recently cut its 2025 sales growth forecast to 8-14% from 13-21% and appointed Maziar Mike Doustdar as CEO, reported Q2 sales of DKK 76.86 billion ($11.92 billion), up 18% but below initial expectations. This strategic pivot aims to counter intensifying competition from rivals like Eli Lilly and compounded versions, as Novo Nordisk battles to maintain its market leadership despite strong Q2 EBIT growth.

Analysis

Novo Nordisk is undertaking a significant strategic pivot, including cost reductions and a sharpened commercial focus, in direct response to severe market pressure that has erased approximately $95 billion from its stock value. This follows a major profit warning and the appointment of a new CEO, Maziar Mike Doustdar. The company's market capitalization has plummeted from a peak of around $650 billion to approximately $212 billion, underscoring a dramatic shift in investor sentiment. The core challenges are twofold: intensifying competition from U.S. rival Eli Lilly and the proliferation of compounded copycat versions of its flagship GLP-1 drugs, Wegovy and Ozempic. While Novo reported an 18% year-over-year increase in second-quarter sales to DKK 76.86 billion, this figure fell short of initial analyst expectations. The company's confirmed cut in its 2025 sales growth forecast to 8%-14%, down from 13%-21% and marking the second such reduction this year, signals a rapidly deteriorating growth outlook that overshadows the reported 29% rise in Q2 EBIT.

Key Decisions for Investors

• Investors should closely scrutinize the new CEO's strategy for achieving cost efficiencies and improved commercial execution, as the stock's recovery is contingent on successfully defending market share against Eli Lilly and generic pressures.
• The repeated downward revision of the 2025 sales forecast warrants a cautious stance, as it indicates persistent headwinds and suggests further valuation pressure is possible until a credible path to stabilizing growth is articulated.
• The explicit threat from compounded drugs under U.S. law represents a key risk factor that could continue to erode revenue from Wegovy and Ozempic, making regulatory monitoring and prescription trend analysis critical.
• Given the negative sentiment for Novo Nordisk (-0.8) and positive sentiment for its primary competitor Eli Lilly (+0.3), a relative value assessment or pair trade could be considered to capitalize on the divergent market momentums within the weight-loss drug sector.